Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.47−0.02 (-4.78%)
Close on Nov 13, 2026Market cap $131.40MP/E –Yield –
Akebia Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Akebia Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -15.7%. For fiscal 2025 it was 9.9%, against -31.5% the year before. The highest annual figure on record is 9.9% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.9% | +41.5 |
| FY2024 | Dec 31, 2024 | -31.5% | −7.7 |
| FY2023 | Dec 31, 2023 | -23.8% | +3.9 |
| FY2022 | Dec 31, 2022 | -27.6% | +97.4 |
| FY2021 | Dec 31, 2021 | -125.0% | +3.3 |
| FY2020 | Dec 31, 2020 | -128.2% | −42.8 |
| FY2019 | Dec 31, 2019 | -85.5% | +0.3 |
| FY2018 | Dec 31, 2018 | -85.8% | −43.5 |
| FY2017 | Dec 31, 2017 | -42.3% | +8847.6 |
| FY2016 | Dec 31, 2016 | -8889.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -31.1% | −38.6 |
| Q2 FY2026 | Jun 30, 2026 | -12.9% | −35.4 |
| Q1 FY2026 | Mar 31, 2026 | -8.8% | −32.3 |
| Q4 FY2025 | Dec 31, 2025 | -14.8% | +15.9 |
| Q3 FY2025 | Sep 30, 2025 | 7.6% | +41.0 |
| Q2 FY2025 | Jun 30, 2025 | 22.6% | +42.5 |
| Q1 FY2025 | Mar 31, 2025 | 23.6% | +69.4 |
| Q4 FY2024 | Dec 31, 2024 | -30.8% | −33.2 |
| Q3 FY2024 | Sep 30, 2024 | -33.4% | −2.4 |
| Q2 FY2024 | Jun 30, 2024 | -20.0% | −4.0 |
| Q1 FY2024 | Mar 31, 2024 | -45.8% | +18.2 |
| Q4 FY2023 | Dec 31, 2023 | 2.4% | +11.2 |
| Q3 FY2023 | Sep 30, 2023 | -31.0% | +72.5 |
| Q2 FY2023 | Jun 30, 2023 | -16.0% | −42.9 |
| Q1 FY2023 | Mar 31, 2023 | -64.0% | +32.6 |
| Q4 FY2022 | Dec 31, 2022 | -8.7% | +104.6 |
| Q3 FY2022 | Sep 30, 2022 | -103.5% | +9.1 |
| Q2 FY2022 | Jun 30, 2022 | 27.0% | +176.9 |
| Q1 FY2022 | Mar 31, 2022 | -96.6% | +27.6 |
| Q4 FY2021 | Dec 31, 2021 | -113.3% | +39.1 |
| Q3 FY2021 | Sep 30, 2021 | -112.6% | −15.7 |
| Q2 FY2021 | Jun 30, 2021 | -149.9% | +42.9 |
| Q1 FY2021 | Mar 31, 2021 | -124.2% | −57.3 |
| Q4 FY2020 | Dec 31, 2020 | -152.4% | −16.0 |
| Q3 FY2020 | Sep 30, 2020 | -96.8% | −36.1 |
| Q2 FY2020 | Jun 30, 2020 | -192.8% | −133.8 |
| Q1 FY2020 | Mar 31, 2020 | -66.8% | +37.7 |
| Q4 FY2019 | Dec 31, 2019 | -136.4% | +14.2 |
| Q3 FY2019 | Sep 30, 2019 | -60.8% | −8.4 |
| Q2 FY2019 | Jun 30, 2019 | -59.0% | +14.0 |
| Q1 FY2019 | Mar 31, 2019 | -104.5% | −51.2 |
| Q4 FY2018 | Dec 31, 2018 | -150.6% | −166.8 |
| Q3 FY2018 | Sep 30, 2018 | -52.4% | +6.2 |
| Q2 FY2018 | Jun 30, 2018 | -73.1% | +4.5 |
| Q1 FY2018 | Mar 31, 2018 | -53.3% | +2425.1 |
| Q4 FY2017 | Dec 31, 2017 | 16.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -58.6% | – |
| Q2 FY2017 | Jun 30, 2017 | -77.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -2478.4% | – |
See a number that looks wrong?